VLN:NYSEValens Semiconductor Ltd. Analysis
Data as of 2026-05-09 - not real-time
$2.79
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Valens Semiconductor (VLN) is trading near its recent resistance of $2.80 with a price of $2.79, while the 20‑day SMA sits at $1.84, well below current levels, indicating short‑term bullish momentum. However, the RSI of 78 signals an overbought condition and the MACD histogram remains positive but modest, suggesting limited upside momentum ahead. The stock’s beta of 2.8 and 30‑day volatility exceeding 130% point to extreme price swings, amplified by a market cap under $300 M and a thin float. Fundamentally, VLN reports strong revenue growth of 16% year‑over‑year but continues to post deep operating losses, negative EPS and a forward P/E of –25, underscoring profitability challenges. Cash balances are healthy at $92.6 M, yet free cash flow remains negative, reflecting ongoing cash burn. The company’s valuation multiples (P/B ≈2.7, price‑to‑sales ≈4.2) appear stretched relative to its earnings profile, and the absence of any dividend eliminates income‑return considerations. Recent news highlights analyst optimism labeling VLN as a “best semiconductor under $10” and upcoming Q1 2026 earnings, which may sustain short‑term interest despite the underlying risk. Overall, the stock presents a mixed picture: technical strength countered by fundamental weakness and high volatility.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price near resistance with overbought RSI
- Bullish MACD but limited histogram expansion
- High short‑term volatility and beta
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Revenue growth offset by persistent operating losses
- Strong cash reserves but negative free cash flow
- Analyst optimism and upcoming earnings release
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- Strategic position in HDBaseT and automotive connectivity markets
- Potential turnaround under new CEO focus on core segments
- Long‑term upside potential reflected in analyst price targets
Key Metrics & Analysis
Financial Health
Revenue Growth16.40%
Profit Margin-44.72%
P/E Ratio-25.4
ROE-25.50%
ROA-13.94%
Debt/Equity7.85
P/B Ratio2.7
Op. Cash Flow$-12718000
Free Cash Flow$-3997000
Industry P/E38.4
Technical Analysis
TrendNeutral
RSI78.5
Support$1.32
Resistance$2.80
MA 20$1.84
MA 50$1.52
MA 200$1.74
MACDBullish
VolumeIncreasing
Fear & Greed Index90.73
Valuation
Target Price$4.00
Upside/Downside43.37%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.83
Volatility131.93%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.